IL51367A0 - Xanthine derivatives - Google Patents

Xanthine derivatives

Info

Publication number
IL51367A0
IL51367A0 IL61367A IL6136777A IL51367A0 IL 51367 A0 IL51367 A0 IL 51367A0 IL 61367 A IL61367 A IL 61367A IL 6136777 A IL6136777 A IL 6136777A IL 51367 A0 IL51367 A0 IL 51367A0
Authority
IL
Israel
Prior art keywords
xanthine derivatives
xanthine
derivatives
Prior art date
Application number
IL61367A
Other languages
English (en)
Original Assignee
Interx Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interx Research Corp filed Critical Interx Research Corp
Publication of IL51367A0 publication Critical patent/IL51367A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL61367A 1976-02-06 1977-02-01 Xanthine derivatives IL51367A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/655,786 US4061753A (en) 1976-02-06 1976-02-06 Treating psoriasis with transient pro-drug forms of xanthine derivatives

Publications (1)

Publication Number Publication Date
IL51367A0 true IL51367A0 (en) 1977-04-29

Family

ID=24630341

Family Applications (1)

Application Number Title Priority Date Filing Date
IL61367A IL51367A0 (en) 1976-02-06 1977-02-01 Xanthine derivatives

Country Status (11)

Country Link
US (1) US4061753A (enEXAMPLES)
AU (1) AU506717B2 (enEXAMPLES)
BE (1) BE851078A (enEXAMPLES)
CA (1) CA1104569A (enEXAMPLES)
DE (1) DE2705025A1 (enEXAMPLES)
FR (1) FR2340318A1 (enEXAMPLES)
GB (1) GB1576351A (enEXAMPLES)
IL (1) IL51367A0 (enEXAMPLES)
IN (1) IN146058B (enEXAMPLES)
SE (1) SE7700971L (enEXAMPLES)
ZA (1) ZA77621B (enEXAMPLES)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275064A (en) * 1976-02-06 1981-06-23 Interx Research Corporation Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents
US4133893A (en) * 1977-05-26 1979-01-09 Calbiochem Behring Corp. Topical treatment of skin diseases
SE416810C (sv) * 1977-10-14 1982-07-19 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
DE2922159A1 (de) * 1979-05-31 1980-12-04 Boehringer Mannheim Gmbh Neue xanthin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DK172081A (da) * 1980-04-21 1981-10-22 Merck & Co Inc Mercaptoforbindelse og fremgangsmaade til fremstilling deraf
US4341783A (en) * 1980-07-31 1982-07-27 Lemmon Company Topical use of dyphylline and dyphylline containing compositions
GB8501488D0 (en) * 1985-01-21 1985-02-20 Beecham Group Plc Treatment
IT1184139B (it) * 1985-01-23 1987-10-22 Proter Spa Composti ad attivita' mucolitica e broncodilatatrice,procedimento per la loro preparazione e composizioni farmaceutiche che licontengono come principi attivi
US4988702A (en) * 1986-08-26 1991-01-29 Warner-Lambert Company Novel 9-deazaguanines
US4923872A (en) * 1986-08-26 1990-05-08 Warner-Lambert Co. Analogues of pyrrolo[3,2d]pyrimidin-4-ones
US4921858A (en) * 1986-10-24 1990-05-01 Warner-Lambert Company 7-deazaguanines as immunomodulators
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
US5886162A (en) * 1989-11-03 1999-03-23 Research Foundation Of State University Of New York Lipophilic diakylaminomethylene prodrug derivatives for the inhibition of replication of viruses
US5726311A (en) * 1989-11-29 1998-03-10 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
JPH05294966A (ja) * 1992-02-17 1993-11-09 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
US5340813A (en) * 1992-11-09 1994-08-23 Cell Therapeutics, Inc. Substituted aminoalkyl xanthine compounds
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
US6117904A (en) * 1999-09-03 2000-09-12 Murphy; Donald M. Treatment of pruritus
US6541517B1 (en) * 1999-09-03 2003-04-01 Donald M. Murphy Treatment of skin disorders
CA2435730C (en) * 2001-02-24 2011-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
RU2196583C1 (ru) * 2001-05-29 2003-01-20 Барбинов Вячеслав Викторович Средство для наружной терапии псориаза и способ его изготовления
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BRPI0313648B8 (pt) * 2002-08-21 2021-05-25 Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-il]-xantinas, seus sais fisiologicamente compatíveis, seus usos e seus processos de preparação, bem como medicamentos que as contêm e seus processos de preparação
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP3542801A1 (en) * 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
PE20110297A1 (es) * 2008-08-15 2011-05-26 Boehringer Ingelheim Int Inhibidores de dpp-4 para la cicatrizacion de heridas
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EA033415B1 (ru) 2010-05-05 2019-10-31 Boehringer Ingelheim Int Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
PL3517539T3 (pl) 2011-07-15 2023-04-24 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
AU2017276758A1 (en) 2016-06-10 2018-11-08 Boehringer Ingelheim International Gmbh Combinations of Linagliptin and metformin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1265879A (fr) * 1960-05-23 1961-07-07 Dérivés substitués en -7 de la théophylline et leurs procédés de préparation
DE1226587B (de) * 1962-07-05 1966-10-13 Josef Klosa Dipl Chem Dr Rer N Verfahren zur Herstellung neuer Theophyllinoaminosaeuren

Also Published As

Publication number Publication date
CA1104569A (en) 1981-07-07
AU2202577A (en) 1978-08-17
US4061753A (en) 1977-12-06
DE2705025A1 (de) 1977-08-11
BE851078A (fr) 1977-05-31
SE7700971L (sv) 1977-08-07
IN146058B (enEXAMPLES) 1979-02-10
ZA77621B (en) 1977-12-28
GB1576351A (en) 1980-10-08
FR2340318A1 (fr) 1977-09-02
AU506717B2 (en) 1980-01-24

Similar Documents

Publication Publication Date Title
IL51367A0 (en) Xanthine derivatives
ZA785335B (en) Xanthine derivatives
PH14332A (en) 4-hydroxyphenylalkanolamine derivatives
IL52002A0 (en) M-phenoxybenzamide derivatives
GB1541547A (en) 4-phenoxymethylpiperidine derivatives
GB1521020A (en) 4-hydrox-aporphine derivatives
ZA772294B (en) Basically substituted xanthine derivatives
ZA771219B (en) Purine derivatives
GB1543124A (en) 2-iminothiazolidine derivatives
GB1554517A (en) Nogarol derivatives
GB1553759A (en) Tetrahyddropyridine derivatives
PT66360B (en) Nicotinoylaminotriazine derivatives
JPS52105138A (en) Novellphenyll22aminoethanol derivatives
GB1523198A (en) Thiazolo-rifamycin derivatives
GB1549755A (en) N-4-halobutyryl derivatives
IL52270A0 (en) Hydrazinopyridazine derivatives
GB1524481A (en) Tetrahydo - imidazopyridine derivatives
GB1545021A (en) 5-norbicyclomycin derivatives
JPS52100431A (en) Anilinoacetate derivatives
GB1535080A (en) Naphthacenequinone derivatives
PH13411A (en) 8-adnantylaninometryl ergolene derivatives
GB1544289A (en) Thiazolinotriazine derivatives
JPS52105159A (en) Estrogene derivatives
JPS5297915A (en) Alkylaminoglucopyranoside derivatives
AU2680877A (en) Arylaminopyrimidine derivatives